Codagenix Inc. utilizes our breakthrough platform technology termed SAVE to construct live-attenuated viral vaccines against multiple targets. All live-attenuated vaccines that are currently used in the clinic were developed using a trial-and-error based method that pre-dates the discovery of the DN…
Codagenix Inc. utilizes our breakthrough platform technology termed SAVE to construct live-attenuated viral vaccines against multiple targets. All live-attenuated vaccines that are currently used in the clinic were developed using a trial-and-error based method that pre-dates the discovery of the DNA double helix. Codagenix presents a breakthrough approach to live-attenuated vaccine design. No longer would a vaccine developer blindly passage their target virus to construct a vaccine. The SAVE platform relies on synthetic biology and the “re-designing” of a target virus’s entire genome to yield a candidate vaccine strain. This technology is a platform technology that utilizes computer-based rational design of viral genomes for the design and construction of vaccines. SAVE was initially applied to poliovirus with great success (Coleman JR Science 2009) and more recently to the human pathogen Influenza A virus (Mueller SM Nature Biotechnology 2010). The technology has proven successful in experimental animal systems; however Codagenix will now pursue utilizing SAVE to yield human vaccines for commercial consumption.
Team (1)
Sectors Codagenix serves:
Life Sciences
Health Care
Join Axial's Private M&A Platform
Codagenix connects with qualified M&A advisors through the Axial Platform.
Looking for Buyers?
Reach this investor and hundreds more on Axial. No cost to advisors.
